Is CC a Buy? What to Consider in 2026

Short answer

The bull case for The Chemours Company (CC) rests on Opteon refrigerant growth: The Thermal & Specialized Solutions segment, anchored by Opteon low-GWP refrigerants, is Chemours' clearest growth engine. Revenue (FY2025) is ~$5.8B. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: PFAS environmental litigation and remediation are the defining risk: Chemours faces thousands of personal injury claims in the AFFF multi-district litigation with bellwether trials that could produce unpredictable damages, on top of the $450 million EPA and DOJ settlement already reached in 2026. Whether CC is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.

The Chemours Company is a US-listed specialty chemicals producer spun out of DuPont in 2015. It reports through three segments: Thermal & Specialized Solutions (refrigerants and thermal management, led by the Opteon low-global-warming-potential product line), Titanium Technologies (TiO2 white pigment used in paints, plastics, and paper), and Advanced Performance Materials (high-end fluoropolymers and advanced materials). Full-year 2025 net sales were roughly $5.8 billion, and the company operates globally across industrial, construction, automotive, and electronics end markets. The investment picture is a barbell. Opteon refrigerants are benefiting from the regulatory phase-down of higher-emission HFCs under the AIM Act, giving Chemours a structurally growing, higher-margin franchise. Against that, the Titanium Technologies business is deeply cyclical and has faced soft pricing and demand tied to construction and coatings, while the company carries substantial, widely reported PFAS environmental and litigation liabilities. Chemours reached a $450 million EPA and DOJ settlement in June 2026 covering several legacy facilities, but AFFF multi-district litigation and other claims remain unresolved, keeping the balance sheet and legal exposure central to how the stock trades.

What's the case for buying CC?

1. Opteon refrigerant growth

The Thermal & Specialized Solutions segment, anchored by Opteon low-GWP refrigerants, is Chemours' clearest growth engine. Regulatory HFC phase-downs under the AIM Act and similar rules abroad are shifting demand toward the newer chemistries Chemours produces. Management has pointed to this franchise as the main driver behind its 2026 guidance for net sales growth of roughly 3 to 5 percent.

2. TiO2 pigment cyclical recovery

Titanium Technologies is the largest revenue segment and is highly sensitive to construction, coatings, and industrial demand. Pricing and volumes have been pressured through the recent cycle, so any recovery in global coatings demand or pigment pricing would be a meaningful earnings lever. The flip side is that continued weakness keeps consolidated margins subdued.

3. Cost, cash flow, and dividend

Chemours has emphasized cost discipline, capital-expenditure control (guided to roughly $275 to $325 million in 2026), and free cash flow conversion above 20 percent. The company pays a modest dividend of about $0.35 per share annually. Delivering on its $800 to $900 million adjusted EBITDA guidance would support the balance sheet and its litigation obligations.

4. PFAS liability resolution

Progress on resolving PFAS exposure is itself a potential catalyst. The June 2026 EPA and DOJ settlement of about $450 million removed some uncertainty at legacy sites. Further settlements or favorable outcomes in the remaining AFFF litigation could reduce the discount the market applies, though the timing and size of remaining liabilities are uncertain.

What are the risks to CC?

PFAS environmental litigation and remediation are the defining risk: Chemours faces thousands of personal injury claims in the AFFF multi-district litigation with bellwether trials that could produce unpredictable damages, on top of the $450 million EPA and DOJ settlement already reached in 2026. The Titanium Technologies segment is cyclical and exposed to weak construction and coatings demand plus low-cost pigment competition. The company posted a net loss in Q1 2026, underscoring thin profitability. Leverage and the cash demands of legal settlements constrain financial flexibility. Regulatory, raw-material, and currency swings add further volatility to results.

How is CC valued? (as of JULY 2026)

Price

$17.39

Market cap

$2.62B

Forward P/E

7.76

Price / book

12.16

Beta

1.40

52-week range

$10.44 to $28.67

Snapshot for CC as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.

Revenue (FY2025): ~$5.8B
Q1 2026 revenue: ~$1.38B
Q1 2026 net loss: ~$29M
2026 adj. EBITDA guide: ~$800-900M
Market cap: ~$3.3B
Dividend yield: ~1.5%

Chemours trades at a low equity valuation relative to its ~$5.8 billion revenue base, reflecting cyclical earnings and PFAS liability overhang rather than a high-growth multiple. Q1 2026 showed revenue up modestly year over year but a net loss, with 2026 guidance calling for 3 to 5 percent sales growth. EV/EBITDA has run in the low-to-mid teens, so much of the enterprise value sits in debt and litigation obligations.

How do you decide if CC is a buy?

Rather than asking whether CC is a buy in the abstract, it tends to help to answer four questions:

Thesis: do you believe the case above, and is it still true today?
Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
Overlap: check whether you already hold CC indirectly through an index or sector ETF before adding more.

For the full picture, see the CC stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about CC against your real portfolio and see your actual exposure before deciding.

The bottom line on CC

The bottom line: The Chemours Company's story right now is Opteon refrigerant growth, with revenue (fy2025) at ~$5.8B. If you believe that narrative continues, the call is about sizing CC sensibly and checking overlap with what you own; if you doubt it (the risk: pFAS environmental litigation and remediation are the defining risk: Chemours faces thousands of personal injury claims in the AFFF multi-district litigation with bellwether trials that could produce unpredictable damages, on top of the $450 million EPA and DOJ settlement already reached in 2026.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.

Build a basket around CC with Walnut

Use The Chemours Company as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.

Create a free Walnut account

FAQ

Is CC a good stock to buy right now?

The case for The Chemours Company right now is Opteon refrigerant growth, with revenue (fy2025) at ~$5.8B. If you believe that thesis holds, CC is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is pFAS environmental litigation and remediation are the defining risk: Chemours faces thousands of personal injury claims in the AFFF multi-district litigation with bellwether trials that could produce unpredictable damages, on top of the $450 million EPA and DOJ settlement already reached in 2026. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.

What does The Chemours Company do?

The Chemours Company is a US-listed specialty chemicals producer spun out of DuPont in 2015.

What are the main risks of CC?

What does Chemours do?

Chemours is a US specialty chemicals company that makes TiO2 white pigment, Opteon low-global-warming-potential refrigerants, and advanced fluoropolymers. It was spun out of DuPont in 2015 and sells into coatings, plastics, refrigeration, automotive, and industrial markets worldwide.

What are Chemours' business segments?

The company reports three segments: Thermal & Specialized Solutions (refrigerants and thermal management), Titanium Technologies (TiO2 pigment), and Advanced Performance Materials (fluoropolymers and advanced materials), plus a smaller Performance Chemicals and Intermediates business.

How much revenue does Chemours generate?

Chemours reported full-year 2025 net sales of roughly $5.8 billion, about flat versus the prior year. First-quarter 2026 revenue was around $1.38 billion, up modestly year over year, though the quarter carried a net loss of about $29 million.

Is Chemours profitable?

Profitability is cyclical and uneven. The company generated positive adjusted earnings in 2025 but reported a net loss of about $29 million in Q1 2026. Its 2026 guidance targets adjusted EBITDA of roughly $800 to $900 million, so cash generation depends heavily on refrigerant demand and pigment pricing.

Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell CC; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.